MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions to flesh out its pipeline, according to chief executive Rob Davis. On the ...